<DOC>
	<DOCNO>NCT00991211</DOCNO>
	<brief_summary>The study address question first line therapy low malignant mantle cell lymphoma bendamustine plus rituximab comparable ( non inferior ) CHOP plus rituximab regard progression free survival ( PFS ) .</brief_summary>
	<brief_title>Bendamustine Plus Rituximab Versus CHOP Plus Rituximab</brief_title>
	<detailed_description>The 4 agent chemotherapy ( CTX ) CHOP ( cyclophosphamide , doxorubicin , vincristine prednisone ) combination monoclonal anti-CD20 antibody rituximab ( CHOP-R ) represent standard CTX treatment lymphomas high low malignancy . The combination bendamustine rituximab ( B-R ) also highly effective advantageous toxicity profile . If B-R could show non inferior CHOP-R , could improve quality life patient possibly also prognosis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients histological verify CD20positive BCellLymphomas follow entity : Follicular lymphoma grade 1 2 Immunocytoma lymphoplasmocytic lymphoma Marginal zone lymphoma , nodal generalise Mantle cell lymphoma lymphocytic lymphoma ( CLL without leucaemic characteristic ) nonspecified/classified lymphomas low malignancy No prior therapy cytotoxics , interferon monoclonal antibody Need therapy , except mantle cell lymphomas Stadium III IV Written inform consent Performance status WHO 02 Histology old 6 month Patients establish mention prerequisite Option primary , potential curative radiation therapy Pretreatment except unique local delimit radiation ( radiation fiel expand two adjacent lymph node region Comorbidities exclude study conform therapy : heart attack last 6 month severe , medicinal adjustable hypertonia severe functional defect heart ( NYHA III IV ) lung ( WHO grade III IV ) , liver kidney ( creatinine &gt; 2 mg/dl , GOT + GPT bilirubin 3 x ULN , except cause lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Comparison</keyword>
	<keyword>Bendamustine + Rituximab</keyword>
	<keyword>CHOP + Rituximab</keyword>
	<keyword>Progression free survival</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Safety</keyword>
</DOC>